ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESM..................*XJDIM360 Ver 1.28 (29 Oct 2014) - 1100000/02870177A120150513EP13732986.82013070320150113enenen201261668134 P20120705US2015051320152020150513201520C07K 16/22 20060101AFI20140129BHEP deOPTIMALER DOSIERUNGSPLAN FÜR EINEN ANTI-NOGO-A-ANTIKÖRPER BEI DER BEHANDLUNG VON AMYOTROPHER LATERALSKLEROSEenOPTIMUM DOSE REGIME OF AN ANTI-NOGO-A ANTIBODY IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSISfrRÉGIME POSOLOGIQUE OPTIMAL D'UN ANTICORPS ANTI-NOGO-A DANS LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUEGlaxo Group Limited101370614AGS/PB65206 EP980 Great West RoadBrentford, Middlesex TW8 9GSGBBULLMAN, JonathanGlaxoSmithKline Gunnels Wood RoadStevenage Hertfordshire SG1 2NYGBKRULL, DavidGlaxoSmithKline Five Moore Drive PO Box 13398 Research Triangle ParkNorth Carolina 27709USSayce, Alastair George101365287GlaxoSmithKline Global Patents (CN925.1) 980 Great West RoadBrentford, Middlesex TW8 9GSGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRBA20150113ME20150113EP201306406320130703enWO201400610520140109201402